Aerovate Therapeutics (AVTE) Earnings Date, Estimates & Call Transcripts $2.60 -0.03 (-1.14%) (As of 12/11/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Aerovate Therapeutics Latest Earnings SummaryActual EPS (Nov. 12) -$0.56 Beat By $0.03 Consensus EPS (Nov. 12) -$0.59 Aerovate Therapeutics announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.56, which beat the consensus estimate of -$0.59 by $0.03. With a trailing EPS of -$2.99, Aerovate Therapeutics' earnings are expected to grow next year, from ($2.64) to ($0.84) per share. Get Aerovate Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAVTE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AVTE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Timothy SykesWARNING: Don’t let the national media distract you Millions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.Click here to watch his emergency briefing >>> Aerovate Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ2 20241-$0.71-$0.71-$0.71Q3 20241-$0.62-$0.62-$0.62Q4 20241-$0.60-$0.60-$0.6020243-$1.93-$1.93-$1.93Q1 20251-$0.41-$0.41-$0.41Q2 20251-$0.31-$0.31-$0.31Q3 20251-$0.25-$0.25-$0.25Q4 20251-$0.17-$0.17-$0.17FY 20254($1.14)($1.14)($1.14) Aerovate Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/12/2024--$0.59-$0.56+$0.03-$0.56--8/12/2024Q2 2024-$0.76-$0.86 -$0.10-$0.86--5/13/2024Q1 2024-$0.74-$0.83 -$0.09-$0.83--3/25/2024Q4 2023-$0.68-$0.74 -$0.06-$0.74--11/13/2023Q3 2023-$0.70-$0.71 -$0.01-$0.71--8/14/2023Q2 2023-$0.69-$0.76 -$0.07-$0.76-- Get the Latest News and Ratings for AVTE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/15/2023Q1 2023-$0.58-$0.67 -$0.09-$0.67--3/29/2023Q4 2022-$0.58-$0.61 -$0.03-$0.61-- Aerovate Therapeutics Earnings - Frequently Asked Questions When did Aerovate Therapeutics announce their last quarterly earnings? Aerovate Therapeutics (NASDAQ:AVTE) last announced its quarterly earning data on Tuesday, November 12, 2024. Learn more on AVTE's earnings history. Did Aerovate Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aerovate Therapeutics (NASDAQ:AVTE) reported ($0.56) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.59) by $0.03. Learn more on analysts' earnings estimate vs. AVTE's actual earnings. How much profit does Aerovate Therapeutics generate each year? Aerovate Therapeutics (NASDAQ:AVTE) has a recorded net income of -$75.52 million. AVTE has generated -$2.99 earnings per share over the last four quarters. What is Aerovate Therapeutics's EPS forecast for next year? Aerovate Therapeutics's earnings are expected to grow from ($2.64) per share to ($0.84) per share in the next year. More Earnings Resources from MarketBeat Related Companies iTeos Therapeutics Earnings Atyr PHARMA Earnings Tenaya Therapeutics Earnings ADC Therapeutics Earnings C4 Therapeutics Earnings Eledon Pharmaceuticals Earnings Rezolute Earnings Benitec Biopharma Earnings UroGen Pharma Earnings ProQR Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings WARNING: Don’t let the national media distract you (Ad)Millions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.Click here to watch his emergency briefing >>> This page (NASDAQ:AVTE) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVance Exposes Wall Street Plan to Crash Bonds, Target TrumpJ.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a deat...Golden Crest | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts